lāʻau maʻi maʻi maʻi hou

Nā holomua hou ma lāʻau maʻi maʻi maʻi hou hāʻawi i ka maikaʻi o ke ola a me ka maikaʻi o ke ola no nā maʻi. Hoʻopili kēia i nā lāʻau lapaʻau i hoʻopaʻa ʻia, immunotherapies, a me nā ʻenehana hoʻomaʻamaʻa holomua. ʻO ka hoʻomaopopo ʻana i kēia mau koho hiki ke hoʻoikaika i nā poʻe maʻi a me ko lākou ʻohana e hoʻoholo i nā hoʻoholo me kā lākou mea mālama olakino. Hāʻawi kēia ʻatikala i kahi hiʻohiʻona o nā holomua hou loa a me nā ala lapaʻau i loaʻa. Understanding Lung Cancer and the Need for New Treatments He mea koʻikoʻi ka hoʻomaopopo ʻana i nā ʻano ʻano like ʻole o ka maʻi maʻi ʻaʻai māmā a me nā kumu e kōkua ai i kona ulu ʻana. ʻO nā lāʻau kuʻuna e like me ka chemotherapy a me ka radiation therapy he mau palena, e hōʻike ana i ka pono wikiwiki lāʻau maʻi maʻi maʻi hou Nā ʻano o ka maʻi maʻi ʻāʻī ʻelua ʻelua ʻano nui: ʻO ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC): ʻO kēia ke ʻano maʻamau, helu ʻia ma kahi o 80-85% o nā hihia maʻi maʻi maʻi. Loaʻa nā subtypes i ka adenocarcinoma, squamous cell carcinoma, a me ka carcinoma cell nui. ʻO ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (SCLC): ʻAʻole maʻamau kēia ʻano a makemake e ulu a palahalaha ʻoi aku ka wikiwiki ma mua o NSCLC. Breakthroughs in Targeted Therapy for Lung CancerTargeted therapy is a lāʻau maʻi maʻi maʻi hou e kālele ana i nā molekole kūikawā i pili i ka ulu ʻana o ka maʻi maʻi a me ke ola. ʻAʻole like me ka chemotherapy, ka mea e hoʻouka i nā pūnaewele wikiwiki a pau, ʻo nā lāʻau lapaʻau i manaʻo ʻia e pepehi i nā maʻi maʻi maʻi ʻoiai e mālama ana i nā mea olakino. Ke alakaʻi pinepine nei kēia i ka liʻiliʻi o nā hopena. Hoʻopili pinepine kēia mau lāʻau lapaʻau i nā hoʻololi i nā genes e like me EGFR, ALK, ROS1, BRAF, MET, a me NTRK. Laʻana Laʻau Laʻau Kūikawā NSCLC Type EGFR Osimertinib (Tagrisso) NSCLC me nā hoʻololi EGFR ALK Alectinib (Alecensa) NSCLC me nā hoʻonohonoho hou ALK ROS1 Entrectinib (Rozlytrek) NSCLC me nā hoʻololi hou o ROS1 Source: ʻAmelika Hui Pū ʻIaʻO ke kuleana o ka hōʻike biomarker ma mua o ka hoʻomaka ʻana i ka lāʻau lapaʻau, pono ka hoʻāʻo biomarker. ʻO kēia hoʻāʻo ʻana e pili ana i ka nānā ʻana i kahi laʻana o ka maʻi maʻi e ʻike ai i nā hoʻololi genetic kikoʻī a i ʻole nā ​​​​mea ʻino ʻole o ka protein. ʻO nā hopena o ka hoʻāʻo biomarker e kōkua i nā kauka e hoʻoholo inā e pōmaikaʻi paha ka mea maʻi mai kahi lāʻau lapaʻau kūikawā. ʻO ka Shandong Baofa Cancer Research Institute Hoʻoikaika i ka pono o ka maʻi maʻi pololei no ka mālama pono ʻana. Immunotherapy: Harnessing the Immune System to Fight Lung CancerImmunotherapy represents another significant progress in lāʻau maʻi maʻi maʻi hou. Hana kēia ʻano hana ma ka hoʻoulu ʻana i ka ʻōnaehana pale ponoʻī o ka mea maʻi e ʻike a hoʻouka i nā maʻi maʻi maʻi. ʻO nā lāʻau lapaʻau Immunotherapy, e like me nā mea hoʻopaneʻe mākaʻikaʻi, poloka i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā cell cancer. ʻO nā mea hoʻopale PD-1: Pembrolizumab (Keytruda), Nivolumab (Opdivo) ʻO nā mea hoʻopaneʻe PD-L1: ʻO Atezolizumab (Tecentriq), Durvalumab (Imfinzi) ʻO nā mea pale CTLA-4: ʻO Ipilimumab (Yervoy) (hoʻohana pinepine ʻia i ka hui pū me ka PD-1 inhibitor) ʻO wai ka moho no ka Immunotherapy? ʻO ka hoʻoholo ʻana e hoʻohana i ka immunotherapy e pili ana i nā kumu he nui, e like me ke ʻano a me ke ʻano o ka maʻi kanesa o ka maʻi, ke olakino holoʻokoʻa o ka mea maʻi, a me ke kiʻekiʻe o ka hōʻike PD-L1 i loko o nā puʻupuʻu tumo. ʻO PD-L1 kahi pūmua e hiki ke kōkua i nā maʻi kanesa e pale aku i ka ʻōnaehana pale. Hiki i nā poʻe maʻi me ka PD-L1 kiʻekiʻe ke pane i ka immunotherapy. E loiloi maikaʻi ʻia ka lāʻau lapaʻau oncologist i kēlā me kēia maʻi e hoʻoholo inā he kūpono ka immunotherapy. lāʻau maʻi maʻi maʻi hou, no ka NSCLC hoʻomaka mua. ʻO ka holomua o nā ʻano hana i alakaʻi ʻia i nā kaʻina hana liʻiliʻi a me nā hopena maikaʻi. Hāʻawi kēia mau ʻenehana i nā mea maikaʻi ma mua o ke kaʻina wehe kuʻuna, me ka liʻiliʻi o ka ʻeha, ka noho ʻana o ka haukapila pōkole, a me ka wikiwiki o ka hoʻōla ʻana. Hāʻawi ʻo SBRT i nā kiʻekiʻe kiʻekiʻe o ka radiation i ka ʻōpū ʻoiai e hōʻemi ana i ka ʻike ʻana i ka ʻiʻo olakino a puni. lāʻau maʻi maʻi maʻi hou pili i ka hoʻohui ʻana i nā lāʻau lapaʻau like ʻole. No ka laʻana, hiki i nā mea maʻi ke loaʻa i ka chemotherapy a ukali ʻia e ka ʻoki ʻana, a i ʻole ka lāʻau lapaʻau i hoʻopaʻa ʻia me ka immunotherapy. ʻO ka hui pū ʻana o nā lāʻau lapaʻau e hilinaʻi ʻia i ke kūlana o kēlā me kēia mea maʻi. ʻO ke koʻikoʻi o nā hoʻāʻo ʻana i nā maʻi. lāʻau maʻi maʻi maʻi hou nā hoʻolālā. ʻO kēia mau ho'āʻo e loiloi i ka palekana a me ka pono o nā lāʻau hou a me nā ala lapaʻau. Hiki i nā poʻe maʻi i komo i nā hoʻokolohua lapaʻau ke loaʻa i nā lāʻau lapaʻau ʻokiʻoki ʻaʻole i loaʻa ākea. E noʻonoʻo e kūkākūkā i nā koho hoʻokolohua lapaʻau me kāu oncologist. Hiki ke loaʻa ka ʻike e pili ana i nā ala lapaʻau e pili ana i ka noiʻi maʻi kanesa ma ka Shandong Baofa Cancer Research Institute website.Living with Lung Cancer: Support and ResourcesA hiki ke lilo i ka ma'i ma'i ma'i 'a'ai. He mea nui e ʻimi i ke kākoʻo mai nā limahana mālama ola, ʻohana, nā hoaaloha, a me nā hui kākoʻo. Nui nā hui e hāʻawi i nā kumuwaiwai a me nā lawelawe e kōkua i nā poʻe maʻi a me ko lākou ʻohana e hoʻokō i nā pilikia o ka noho ʻana me ka maʻi maʻi ʻāʻī. lāʻau maʻi maʻi maʻi hou i nā makahiki i hala iho nei. Hāʻawi nā lāʻau lapaʻau i hoʻopaʻa ʻia, immunotherapies, a me nā ʻenehana hoʻomaʻamaʻa kiʻekiʻe i ka manaʻolana hou no nā poʻe maʻi me ka maʻi kanesa. Ma ka hoʻomau ʻana i ka ʻike e pili ana i nā holomua hou loa a me ka hana pū ʻana me kā lākou hui mālama olakino, hiki i nā mea maʻi ke hoʻoholo i ka ʻike a hoʻomaikaʻi i ko lākou kūlana ola a me ka maikaʻi o ke ola.